Clinical Trial Update: Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intravitreal autologous CD34+ stem cell therapy for Retinitis Pigmentosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• Autologous CD34+ stem cell therapy (intravitreal) (CD34+ stem cells)

Snippet

Sponsor: University of California, Davis | Conditions: Retinitis Pigmentosa | Phase 1 | Status: COMPLETED